Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman.
OBJECTIVE
To describe a case of oral valproic acid-induced hyperammonemia and thrombocytopenia in an elderly patient.


METHODS
A 76-year-old white woman presented to the emergency department with generalized weakness, confusion, nausea, and vomiting. She was taking sodium divalproex 750 mg 3 times daily, with valproic acid concentration 144 mg/L. She was admitted to the medical ward. The dose of sodium divalproex was decreased and discontinued. During her hospital stay, the woman's ammonia level rose to 211 microg/dL despite a normal valproic acid concentration. She was confused, somnolent, and had decreased mobility. Her platelet count decreased from 133 to 86 x 10(3)/mm(3). Gabapentin was prescribed for seizure control. The patient's mental status, ammonia level, and platelet count returned to baseline following discontinuation of valproic acid.


CONCLUSIONS
It has been reported that valproic acid can interfere with the enzyme carbamoylphosphate synthetase, which is responsible for incorporating ammonia into the urea cycle. It has also been reported that valproic acid can increase the transport of glutamine across the mitochondrial membrane in the kidney, thereby increasing the production of ammonia. The etiology of valproic acid-induced thrombocytopenia has not been elucidated. Using the Naranjo probability scale, a probable relationship between hyperammonemia and valproic acid and a possible relationship between thrombocytopenia and valproic acid were determined.


CONCLUSIONS
Valproic acid can be associated with hyperammonemia and thrombocytopenia. Clinicians should be aware of changes in patients' cognitive and functional capacity, especially elderly patients on sodium divalproex.
Mallet
Louise
L
Faculty of Pharmacy, University of in Geriatrics, McGill University Health Centre, Royal Victoria Hospital, Montreal, Quebec, Canada. louise.mallet@umontreal.ca
Babin
Steve
S
Morais
José A
JA
D000368:Aged; D000641:Ammonia / Q000097:blood; D000927:Anticonvulsants / Q000009:adverse effects*; D005260:Female; D006801:Humans; D022124:Hyperammonemia / Q000139:chemically induced*; D010976:Platelet Count; D013921:Thrombocytopenia / Q000139:chemically induced; D014635:Valproic Acid / Q000009:adverse effects* / Q000097:blood
D000927:Anticonvulsants; D014635:Valproic Acid; D000641:Ammonia